LabConnect to Showcase Innovative Ambient Sample Shipping System at DIA
Logistics can be one of the most complex aspects of successful clinical trials because samples shipped from study sites for testing at a central laboratory may come with very limited temperature range requirements. LabConnect, an innovative provider of central laboratory solutions, will be demonstrating how its Snuggy Clinical Kit, an ambient specimen shipping system, reduces weight and logistical costs and saves investigative sites valuable time and storage space at the Drug Information Association (DIA) annual meeting.
“Logistics can account for as much as 40 percent of the total cost of a clinical trial, and large bulky shippers are a huge irritant to sites,” said LabConnect President and CEO Eric Hayashi. “Validated cold-chain solutions are expensive, so controlled ambient shipping solutions like the Snuggy Clinical Kit are becoming increasingly important in PBMC and other analyses where high cellular viability and yields are critical.”
The Snuggy Clinical Kit was initially custom-designed for a two-year clinical study of progressive multiple sclerosis.
“We set out to develop a compact shipping system to save sites space and save our clients money while maintaining the test tubes within a very limited target temperature range,” Hayashi said. In multiple tests exposing the Snuggy Clinical Kit to extreme heat and cold, temperature variability remained well within the client’s requirements.
“When our custom kits are combined with our vast network of local laboratories around the world, shipping distances are reduced; therefore, significant savings in logistics are possible,” Hayashi said.
In addition to custom kit-building, LabConnect’s services to the biopharmaceutical industry include routine and specialized testing, biostorage and scientific operations support services utilizing advanced data management and reporting systems. To see a demonstration of the Snuggy Clinical Kit, an ambient specimen shipping system, visit LabConnect in booth #616 at DIA.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
